B+
Bull case
25%
Probability
Target price
$68.39
Analysis reference price unavailable
Analysis 2025-10-10 · RankAlpha Sentiment AI
TEM
Tempus AIDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
55%
Probability
Target price
$44.12
Analysis reference price unavailable
Analysis 2025-10-10 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$28.24
Analysis reference price unavailable
Analysis 2025-10-10 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-10-10
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+37.9
Score
AI commentary
Market sentiment is mixed-to-constructive: investors note meaningful long-term opportunity in AI-driven diagnostics but remain cautious on execution, margins, and near-term cash flow. Volatility typically spikes around earnings and regulatory updates.
RankAlpha Sentiment AI - 2025-10-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventQuarterly earnings releaseHigh impact
Upcoming quarterly results and guidance are likely to reset consensus on revenue growth and margins and cause near-term share volatility.
-catalystCommercial partnerships and dataset expansionHigh impact
Securing major enterprise contracts or expanding datasets would validate revenue durability and support multiple expansion over 12–24 months.
Recommendation
N/A
No formal recommendation provided.
As of 2025-10-10 • Updated nightlySource: Internal modelMethodology